A Study To Evaluate The Correlation Between Frailty, Adverse Outcome And Clonal Hematopoiesis

Overview

About this study

The purpose of this study is to assess the frailty and clonal hematopoiesis (CH) in hematology malignancy patients.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

All Patients > 18 years with a diagnosis of myeloid malignancy or CHIP willing and able to provide written informed consent.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Mrinal Patnaik, M.B.B.S.

Closed for enrollment

Contact information:

Mrinal Patnaik

5075380173

patnaik.mrinal@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20502516

Mayo Clinic Footer